Company: CRVO
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001437749-25-013543
Chunk: 62

Company: CervoMed Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 62
---
 that the Company may recover from a participant any compensation received from any incentive award (whether or not settled) or cause a participant to forfeit any incentive award (whether or not vested) in the event that the Company’s Clawback Policy as then in effect is triggered. |

Background for Shares Authorized for Issuance Under the 2025 Plan

If the 2025 Plan is approved, the maximum aggregate number of shares of our common stock authorized for issuance pursuant to awards under the 2025 Plan, subject to adjustment, will be 800,000 shares.

<div align='center'>33</div>

In setting the number of shares of common stock authorized for issuance under the 2025 Plan, we considered a number of factors, which are discussed further below, including:

| ● | Total outstanding equity awards, shares to be authorized for issuance under the 2025 Plan and how long the shares proposed to be authorized for issuance under the 2025 Plan are expected to last; |

| ● | Historical equity award granting practices, including our three-year average burn rate, and our anticipated equity award granting practices; and |

| ● | Potential dilution. |

Total Outstanding Equity Awards and Shares Available under the 2025 Plan. While the use of long-term incentives, in the form of equity awards, is an important part of our compensation program, we are mindful of our responsibility to our stockholders to exercise judgment in the granting of equity awards. In setting the number of shares authorized for issuance under the 2025 Plan, we considered total outstanding equity awards, shares to be available under the 2025 Plan and how long the shares available under the 2025 Plan are expected to last. Under the heading “—Securities Authorized for Issuance under Equity Compensation Plans” on page 41, as required by SEC rules, we provide information about shares of our common stock that may be issued under outstanding equity compensation arrangements as of December 31, 2024. To facilitate the approval of the 2025 Plan, set forth below is certain additional information as of the Record Date, April 24, 2025.

As of the Record Date, we had 8,702,719 shares of common stock issued and outstanding. The market value of one share of our common stock on the Record Date, as determined by reference to the closing price of our common stock, as reported on the Nasdaq Capital Market, was $8.80.

As of the Record Date:

| ● | 67,345 shares of our